Gain-of-function genetic variants in LPL2,3 and loss-of-function variants in its intravascular inhibitors ANGPTL3,4,5,6ANGPTL4,2,7 and APOC38,9 are associated with lower triglyceride levels and lower coronary disease risk, while loss-of-function variants in LPL2,3,10 and its natural activator APOA511 are associated with higher triglyceride levels and higher coronary risk. This evidence concerns the gene ANGPTL3 and coronary artery disorder.